Clinical Trial Update: Registry on the Effectiveness and Safety of the 9-month MDR-END Treatment Regimen in Korean Patients with FQ-sensitive MDR-TB (MDR-END Registry)

View source ↗

Summary

This is a clinical trial registry entry for the 9-month MDR-END treatment regimen for fluoroquinolone-sensitive multidrug-resistant tuberculosis in Korean patie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multidrug-resistant Tuberculosis

Drugs mentioned

• MDR-END regimen

Snippet

Sponsor: Korea Otsuka Pharmaceutical Co., Ltd. | Conditions: Tuberculosis, Multidrug-Resistant | Status: NOT_YET_RECRUITING